Real-Time Reverse Transcription-Polymerase Chain Reaction Assay Panel for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 and Its Variants
The global COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has underscored the critical need for accurate and adaptable diagnostic tools. As the virus evolves, emerging variants with mutations in key genomic regions threaten to compromise the sensitivity of existing nucleic acid-based tests. This challenge necessitates continuous refinement of detection methods to ensure reliable diagnosis and surveillance. A recent study developed a panel of real-time reverse transcription-polymerase chain reaction (rRT-PCR) assays targeting conserved and variable regions of the SARS-CoV-2 genome, enabling the detection of the virus and its variants of concern (VOCs).
Background and Rationale
SARS-CoV-2 variants, characterized by mutations in the spike (S) protein and other genomic regions, have raised concerns about diagnostic accuracy. For instance, lineage B.1.1.7 (Alpha) and B.1.351 (Beta), classified as VOCs by the World Health Organization (WHO), carry mutations such as N501Y and E484K, which enhance transmissibility and immune evasion. These mutations can also disrupt primer or probe binding in rRT-PCR assays, leading to false-negative results. To address this, the study focused on designing assays targeting regions with lower mutation rates, such as the RNA-dependent RNA polymerase (RdRp) and nucleocapsid (N) genes, while also developing variant-specific assays for key S gene mutations.
Development of rRT-PCR Assays
Four rRT-PCR assays were developed and validated:
- RdRp Assay: Targets the RdRp gene (genomic positions 15,470–15,544), critical for viral replication.
- N9 Assay: Targets the N gene (positions 28,322–28,455), selected for its high transcription levels during infection.
- S484K Assay: Detects the E484K mutation in the S gene, characteristic of the B.1.351 lineage.
- S501Y Assay: Identifies the N501Y mutation in the S gene, associated with the B.1.1.7 lineage.
Primers and probes were designed using Primer Premier software and aligned against multiple SARS-CoV-2 sequences, including VOCs (B.1.1.7, B.1.351) and variants of interest (VOIs). The RdRp and N9 assays were chosen for their conserved regions, minimizing mismatches with circulating variants. The S484K and S501Y assays were designed to specifically recognize mutations linked to immune evasion and increased transmissibility.
Analytical Sensitivity and Specificity
The assays were evaluated using a SARS-CoV-2 RNA standard with predetermined genomic copies. Serial dilutions demonstrated a detection limit of 5 copies per reaction for the RdRp, N9, and ORF1ab assays, while the N assay had a slightly higher limit of 10 copies per reaction. Amplification efficiency ranged between 98.5% and 103.5%, with linear correlation coefficients (R²) exceeding 0.999 across a dynamic range of seven orders of magnitude (5–5×10⁶ copies/reaction).
Specificity testing confirmed no cross-reactivity with six other human coronaviruses: 229E, OC43, NL63, HKU1, SARS-CoV, and MERS-CoV. This specificity ensures reliable differentiation of SARS-CoV-2 from related pathogens, even in co-circulating scenarios.
Duplex Assays for VOC Detection
To streamline variant screening, duplex rRT-PCR assays were developed by combining the ORF1ab assay (targeting conserved ORF1ab regions) with the S484K or S501Y assays. These duplex setups allowed simultaneous detection of SARS-CoV-2 and identification of VOCs:
- The ORF1ab/S484K duplex detected B.1.351 lineage viruses, with the S484K probe generating signals only in the presence of the E484K mutation.
- The ORF1ab/S501Y duplex identified B.1.1.7 lineage viruses, with the S501Y probe specific to the N501Y mutation.
Both duplex assays maintained high sensitivity, with the S501Y assay performing equivalently to ORF1ab, while the S484K assay showed marginally lower sensitivity. These assays provide a rapid and cost-effective method for preliminary VOC screening without requiring full genome sequencing.
Implications for Diagnostic Adaptation
The study highlighted the importance of monitoring primer-probe mismatches caused by viral evolution. For example, the original N assay exhibited six mismatches in the forward primer when aligned with newer variants, risking reduced sensitivity. By contrast, the RdRp and N9 assays, targeting more conserved regions, demonstrated robustness against emerging mutations. This adaptability is crucial for maintaining diagnostic accuracy as the virus evolves.
Additionally, the S484K and S501Y assays exemplify a targeted approach to VOC surveillance. By focusing on high-impact mutations associated with public health risks, these assays enable laboratories to prioritize resources for variants with proven epidemiological significance.
Technical Validation and Workflow Integration
The rRT-PCR protocols utilized the AgPath-ID™ One-Step RT-PCR Kit, with reactions optimized for 25 µL volumes containing 12.5 µL of 2× buffer, 1 µL enzyme mix, and 5 µL RNA template. Thermal cycling conditions included reverse transcription at 45°C for 10 minutes, followed by 40 cycles of denaturation (95°C for 15 seconds) and annealing/extension (60°C for 1 minute). Each run incorporated controls for extraction, amplification, and template integrity.
The integration of these assays into existing diagnostic workflows enhances surveillance capabilities. For instance, laboratories can employ the RdRp and N9 assays as primary tests for broad SARS-CoV-2 detection, reserving S484K and S501Y assays for confirmatory VOC testing. This tiered approach balances sensitivity, specificity, and operational efficiency.
Future Directions
While the current panel addresses key mutations in B.1.1.7 and B.1.351, ongoing surveillance is needed to track emerging variants with mutations such as L452R (Delta variant) or E484Q (Kappa variant). The study’s methodology—combining conserved gene targets with mutation-specific probes—provides a template for rapid assay development in response to new VOCs.
Conclusion
The development of RdRp, N9, S484K, and S501Y rRT-PCR assays represents a significant advancement in SARS-CoV-2 diagnostics. By balancing conserved targets for broad detection and mutation-specific probes for VOC identification, this panel addresses the dual challenges of sensitivity and adaptability. As the pandemic evolves, such tools will remain indispensable for timely outbreak response and informed public health decision-making.
doi.org/10.1097/CM9.0000000000001687
Was this helpful?
0 / 0